Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma

This is a randomized, double-blind, parallel group, placebo-controlled study designed to
evaluate the efficacy and safety of a fixed 300 mg dose of tralokinumab administered
subcutaneously every 2 weeks in adult and adolescent subjects with oral corticosteroid
dependent asthma. Approximately120 subjects will be randomized globally. Subjects will
receive tralokinumab or placebo, administered via subcutaneous injection at the study site,
over a 40-week treatment period.

Inclusion Criteria:

1) Age 12-75 2) Documented physician-diagnosed asthma. 3) Documented treatment with ICS at
a total daily dose corresponding to ≥500µg fluticasone propionate dry powder formulation
and a LABA. 4) Subjects must have received OCS for the treatment of asthma for 6 months
prior to Visit 1 and on a stable OCS dose between ≥7.5 to ≤30mg daily or daily equivalent
for at least one month prior to enrolment (Visit 1) . 5) Pre-BD FEV1 value <80% (<90% for
patients 12-17 yrs of age) of their PNV. 6) Post-BD reversibility of ≥12% in FEV1.

Exclusion Criteria:

1) Clinically important pulmonary disease other than asthma. 2) History of anaphylaxis
following any biologic therapy. 3) Hepatitis B, C or HIV. 4) Pregnant or breastfeeding. 5)
History of cancer. 6) Current tobacco smoking or a history of tobacco smoking for ≥10
pack-years. 7) Previous receipt of tralokinumab.